Cancers (Mar 2022)

Comparison of Active Surveillance to Stereotactic Radiosurgery for the Management of Patients with an Incidental Frontobasal Meningioma—A Sub-Analysis of the IMPASSE Study

  • Abdurrahman I. Islim,
  • Georgios Mantziaris,
  • Stylianos Pikis,
  • Ching-Jen Chen,
  • Adomas Bunevicius,
  • Selçuk Peker,
  • Yavuz Samanci,
  • Ahmed M. Nabeel,
  • Wael A. Reda,
  • Sameh R. Tawadros,
  • Amr M. N. El-Shehaby,
  • Khaled Abdelkarim,
  • Reem M. Emad,
  • Violaine Delabar,
  • David Mathieu,
  • Cheng-Chia Lee,
  • Huai-Che Yang,
  • Roman Liscak,
  • Jaromir May,
  • Roberto Martinez Alvarez,
  • Nuria Martinez Moreno,
  • Manjul Tripathi,
  • Douglas Kondziolka,
  • Herwin Speckter,
  • Camilo Albert,
  • Greg N. Bowden,
  • Ronald J. Benveniste,
  • Lawrence Dade Lunsford,
  • Jason P. Sheehan,
  • Michael D. Jenkinson

DOI
https://doi.org/10.3390/cancers14051300
Journal volume & issue
Vol. 14, no. 5
p. 1300

Abstract

Read online

Meningioma is a common incidental finding, and clinical course varies based on anatomical location. The aim of this sub-analysis of the IMPASSE study was to compare the outcomes of patients with an incidental frontobasal meningioma who underwent active surveillance to those who underwent upfront stereotactic radiosurgery (SRS). Data were retrospectively collected from 14 centres. The active surveillance (n = 28) and SRS (n = 84) cohorts were compared unmatched and matched for age, sex, and duration of follow-up (n = 25 each). The study endpoints included tumor progression, new symptom development, and need for further intervention. Tumor progression occurred in 52.0% and 0% of the matched active surveillance and SRS cohorts, respectively (p p = 0.329). No patients in the matched cohorts developed symptoms attributable to treatment. Three patients managed with active surveillance (10.7%, unmatched; 12.0%, matched) underwent an intervention for tumor growth with no persistent side effects after treatment. No patients subject to SRS underwent further treatment. Active monitoring and SRS confer a similarly low risk of symptom development. Upfront treatment with SRS improves imaging-defined tumor control. Active surveillance and SRS are acceptable treatment options for incidental frontobasal meningioma.

Keywords